The Asia Pacific hyperpigmentation disorder treatment market was valued at US$ 2,462.36 million in 2022 and is expected to reach US$ 4,468.99 million by 2030; it is estimated to register a CAGR of 7.7% from 2022 to 2030.
Strategic Initiatives by Market Players Boost Asia Pacific Hyperpigmentation Disorder Treatment Market
Major hyperpigmentation disorder treatment market players focus on research and development activities to develop and launch innovative and efficient products. They are also making efforts to win regulatory approvals for their products. Some of the recent product developments and launches, which are likely to create ample growth opportunities for market players, are mentioned as; In October 2022, Galderma introduced Skincare A-LUMINATE BRIGHTENING SERUM, a breakthrough product in the skincare industry. This innovative addition to the ALASTIN Skincare range is specifically formulated to lower the appearance of surface hyperpigmentation without the use of harsh or irritating ingredients. In February 2022, Alchemee introduced the new Restorative Elements brand to help in the correction of the appearance of various types of skin discoloration and hyperpigmentation symptoms, including age spots, sun spots, uneven skin tone, and post-inflammatory hyperpigmentation (PIH). The Restorative Elements is a dermatologist-developed, clinically-proven routine formulated to safely and gently help fade the visible signs of skin hyperpigmentation. In May 2022, Scientis launched the Cyspera Intensive System, a three-product system formulated to improve hyperpigmentation.
Asia Pacific Hyperpigmentation Disorder Treatment Market Overview
Various factors promoting growth of the healthcare sector in India include an aging population, increasing income, and affordability, leading to higher demand and adoption of healthcare and cosmetics services. Hyperpigmentation disorders are prevalent in India; most of these disorders are attributed to or aggravated by solar exposure. Indian population also presents a large variety of sun-induced skin damage, including photoaging and hyperpigmentation. According to a study conducted in February 2022 at a tertiary healthcare center in Western Odisha, India, published in the “Journal of Clinical and Diagnostic Research, India,” Indian men with the Fitzpatrick skin type IV receiving average sun exposure of 7.4 hours/day showed a higher prevalence of melasma; these men were from the age group of 31–35 and categorized under the lower middle class. A higher Melasma Area Severity Index (MASI) score was noted in higher Fitzpatrick skin types (IV/V) with greater sun exposure durations. As the prevalence of melasma grows, the demand for hyperpigmentation disorder treatment also increases in India.
Asia Pacific Hyperpigmentation Disorder Treatment Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Hyperpigmentation Disorder Treatment Market Segmentation
The Asia Pacific hyperpigmentation disorder treatment market is categorized into treatment type, condition, end user, and country.
By treatment type, the Asia Pacific hyperpigmentation disorder treatment market is segmented into cosmeceutical, light or laser therapy, microdermabrasion, chemical peels, cryotherapy, and others. The cosmeceutical segment held the largest share of the Asia Pacific hyperpigmentation disorder treatment market share in 2022.
In terms of condition, the Asia Pacific hyperpigmentation disorder treatment market is segmented into melasma, solar lentigines, post-inflammatory hyperpigmentation, and others. The melasma segment held the largest share of the Asia Pacific hyperpigmentation disorder treatment market share in 2022.
By end user, the Asia Pacific hyperpigmentation disorder treatment market is hospitals, dermatology centers, and others. The hospital segment held the largest share of the Asia Pacific hyperpigmentation disorder treatment market share in 2022.
Based on country, the Asia Pacific hyperpigmentation disorder treatment market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. India segment held the largest share of Asia Pacific hyperpigmentation disorder treatment market in 2022.
AbbVie Inc, Bayer AG, Galderma SA, L’OREAL S.A., Lutronic Co Ltd, Obagi Cosmeceuticals LLC, and Pierre Fabre SA are some of the leading companies operating in the Asia Pacific hyperpigmentation disorder treatment market.
Asia Pacific Hyperpigmentation Disorder Treatment Market Strategic Insights
Asia Pacific Hyperpigmentation Disorder TreatmentMarket Report Highlights
| Report Attribute | Details |
| Market size in 2022 | US$ 2,462.36 Million |
| Market Size by 2030 | US$ 4,468.99 Million |
| CAGR (2022 - 2030) | 7.7% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Treatment Type
|
|
Regions and Countries Covered
|
|
| Asia Pacific | China, India, Japan, Australia, Rest of Asia-Pacific |
| Market leaders and key company profiles |
|
Asia Pacific Hyperpigmentation Disorder Treatment Market Country and Regional Insights
